adenine has been researched along with Idiopathic Parkinson Disease in 26 studies
Excerpt | Relevance | Reference |
---|---|---|
"Congenital hydrocephalus (CH) is caused by genetic mutations, but whether factors impacting human genetic mutations are disease-specific remains elusive." | 2.72 | Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions. ( Hart, C; McKnight, I; Park, IH; Shim, JW, 2021) |
"At the molecular level, Parkinson's disease share common molecular signatures with most neurodegenerative diseases including the accumulation of misfolded proteins in the brain." | 2.61 | Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease. ( Gonzalez, C; Hetz, C; Lopez, N; Martinez, A, 2019) |
"Neurodegenerative diseases are characterized by the aggregation of misfolded proteins in the brain." | 2.50 | Prions: generation and spread versus neurotoxicity. ( Halliday, M; Mallucci, GR; Radford, H, 2014) |
"Baicalein was administrated from 7 to 12 week." | 1.46 | Baicalein Protects against Rotenone-Induced Neurotoxicity through Induction of Autophagy. ( Cao, X; Kuang, L; Lu, Z, 2017) |
"L-Dopa, the standard therapeutic for Parkinson's disease, is inactivated by the enzyme catechol-O-methyltransferase (COMT)." | 1.37 | Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors. ( Borroni, E; Diederich, F; Ehler, A; Ellermann, M; Jakob-Roetne, R; Lerner, C; Paulini, R; Roth, D; Rudolph, MG; Schlatter, D; Schweizer, WB, 2011) |
"Monogenic forms of Parkinson's disease (PD) provide an opportunity to examine mechanisms underlying phenotypic variation." | 1.34 | Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease. ( Athanassiadou, A; Bonifati, V; Di Iorio, G; Golbe, LI; Johnson, WG; Markopoulou, K; Papapetropoulos, S; Spychala, JR; Stenroos, ES; Vance, JM; Watts, RL; Williams, TA, 2007) |
"All compounds tested reversed the catalepsy induced by haloperidol." | 1.33 | New adenosine A2A receptor antagonists: actions on Parkinson's disease models. ( Cristalli, G; Morelli, M; Pinna, A; Volpini, R, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (3.85) | 18.7374 |
1990's | 1 (3.85) | 18.2507 |
2000's | 9 (34.62) | 29.6817 |
2010's | 13 (50.00) | 24.3611 |
2020's | 2 (7.69) | 2.80 |
Authors | Studies |
---|---|
Pupyshev, AB | 1 |
Tenditnik, MV | 1 |
Ovsyukova, MV | 1 |
Akopyan, AA | 1 |
Dubrovina, NI | 1 |
Tikhonova, MA | 1 |
McKnight, I | 1 |
Hart, C | 1 |
Park, IH | 1 |
Shim, JW | 1 |
Kuang, L | 1 |
Cao, X | 1 |
Lu, Z | 1 |
Martinez, A | 1 |
Lopez, N | 1 |
Gonzalez, C | 1 |
Hetz, C | 1 |
Yang, F | 1 |
Yang, YP | 1 |
Mao, CJ | 1 |
Liu, L | 1 |
Zheng, HF | 1 |
Hu, LF | 1 |
Liu, CF | 1 |
Piersanti, G | 1 |
Bartoccini, F | 1 |
Lucarini, S | 1 |
Cabri, W | 1 |
Stasi, MA | 1 |
Riccioni, T | 1 |
Borsini, F | 2 |
Tarzia, G | 1 |
Minetti, P | 1 |
Endo, K | 1 |
Deguchi, K | 1 |
Matsunaga, H | 1 |
Tomaya, K | 1 |
Yamada, K | 1 |
Halliday, M | 1 |
Radford, H | 1 |
Mallucci, GR | 1 |
Yakhine-Diop, SM | 1 |
Bravo-San Pedro, JM | 1 |
Gómez-Sánchez, R | 1 |
Pizarro-Estrella, E | 1 |
Rodríguez-Arribas, M | 1 |
Climent, V | 1 |
Aiastui, A | 1 |
López de Munain, A | 1 |
Fuentes, JM | 1 |
González-Polo, RA | 1 |
Zhang, Y | 1 |
Wu, JY | 1 |
Weng, LH | 1 |
Li, XX | 1 |
Yu, LJ | 1 |
Xu, Y | 1 |
Volpini, R | 4 |
Dal Ben, D | 1 |
Lambertucci, C | 1 |
Marucci, G | 2 |
Mishra, RC | 1 |
Ramadori, AT | 1 |
Klotz, KN | 1 |
Trincavelli, ML | 1 |
Martini, C | 1 |
Cristalli, G | 4 |
Finaurini, S | 1 |
Buccioni, M | 1 |
Lammi, C | 1 |
Kandhavelu, M | 1 |
Ricciutelli, M | 1 |
Angeli, P | 1 |
Commandeur, JN | 1 |
Pinna, A | 4 |
Tronci, E | 1 |
Schintu, N | 1 |
Simola, N | 1 |
Pontis, S | 2 |
Morelli, M | 3 |
Oses, JP | 1 |
Batassini, C | 1 |
Pochmann, D | 1 |
Böhmer, AE | 1 |
Vuaden, FC | 1 |
Silvestrin, RB | 1 |
Oliveira, A | 1 |
Bonan, CD | 1 |
Bogo, MR | 1 |
Souza, DO | 1 |
Portela, LV | 1 |
Sarkis, JJ | 1 |
Mello e Souza, T | 1 |
Hassin-Baer, S | 1 |
Hattori, N | 1 |
Cohen, OS | 1 |
Massarwa, M | 1 |
Israeli-Korn, SD | 1 |
Inzelberg, R | 1 |
Ellermann, M | 1 |
Paulini, R | 1 |
Jakob-Roetne, R | 1 |
Lerner, C | 1 |
Borroni, E | 1 |
Roth, D | 1 |
Ehler, A | 1 |
Schweizer, WB | 1 |
Schlatter, D | 1 |
Rudolph, MG | 1 |
Diederich, F | 1 |
Jiang, TF | 1 |
Zhang, YJ | 1 |
Zhou, HY | 1 |
Wang, HM | 1 |
Tian, LP | 1 |
Liu, J | 1 |
Ding, JQ | 1 |
Chen, SD | 1 |
GOMIRATO, G | 1 |
HYDEN, H | 1 |
Golbe, LI | 1 |
Di Iorio, G | 1 |
Markopoulou, K | 1 |
Athanassiadou, A | 1 |
Papapetropoulos, S | 1 |
Watts, RL | 1 |
Vance, JM | 1 |
Bonifati, V | 1 |
Williams, TA | 1 |
Spychala, JR | 1 |
Stenroos, ES | 1 |
Johnson, WG | 1 |
Vilar, R | 1 |
Coelho, H | 1 |
Rodrigues, E | 1 |
Gama, MJ | 1 |
Rivera, I | 1 |
Taioli, E | 1 |
Lechner, MC | 1 |
Lücking, CB | 1 |
Kösel, S | 1 |
Mehraein, P | 1 |
Graeber, MB | 1 |
Loeffler, DA | 1 |
Camp, DM | 1 |
Juneau, PL | 1 |
Harel, E | 1 |
LeWitt, PA | 1 |
Barbieri, S | 1 |
Hofele, K | 1 |
Wiederhold, KH | 1 |
Probst, A | 1 |
Mistl, C | 1 |
Danner, S | 1 |
Kauffmann, S | 1 |
Sommer, B | 1 |
Spooren, W | 1 |
Tolnay, M | 1 |
Bilbe, G | 1 |
van der Putten, H | 1 |
5 reviews available for adenine and Idiopathic Parkinson Disease
Article | Year |
---|---|
Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions.
Topics: Adenine; Alzheimer Disease; Animals; Carrier Proteins; Chromosome Mapping; Chromosomes; Databases, G | 2021 |
Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease.
Topics: Adenine; Adrenergic alpha-2 Receptor Agonists; Animals; Disease Models, Animal; Endoplasmic Reticulu | 2019 |
Prions: generation and spread versus neurotoxicity.
Topics: Adenine; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; eIF-2 Kinase; Humans; I | 2014 |
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials, Phase I | 2009 |
Mouse models of alpha-synucleinopathy and Lewy pathology. Alpha-synuclein expression in transgenic mice.
Topics: Adenine; alpha-Synuclein; Alzheimer Disease; Animals; Brain; Disease Models, Animal; Humans; Lewy Bo | 2001 |
21 other studies available for adenine and Idiopathic Parkinson Disease
Article | Year |
---|---|
Restoration of Parkinson's Disease-Like Deficits by Activating Autophagy through mTOR-Dependent and mTOR-Independent Mechanisms in Pharmacological and Transgenic Models of Parkinson's Disease in Mice.
Topics: Adenine; Animals; Autophagy; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Transgenic; MTO | 2021 |
Baicalein Protects against Rotenone-Induced Neurotoxicity through Induction of Autophagy.
Topics: Adenine; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dop | 2017 |
Crosstalk between the proteasome system and autophagy in the clearance of α-synuclein.
Topics: Adenine; alpha-Synuclein; Animals; Autophagy; Cell Survival; Chymotrypsin; Humans; Oligopeptides; Pa | 2013 |
Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Binding, Competitive; CHO Cel | 2013 |
8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Antipsychotic Agents; Cat | 2014 |
G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy.
Topics: 1-Methyl-4-phenylpyridinium; Adenine; Autophagy; Case-Control Studies; Caspases; Cells, Cultured; Do | 2014 |
Valproic acid protects against MPP
Topics: 1-Methyl-4-phenylpyridinium; Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Humans; | 2017 |
Adenosine A2A receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Binding Sites; Computer Simulation; Crystallogr | 2009 |
In vitro metabolism studies of new adenosine A 2A receptor antagonists.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Chromatography, High Pressure Liquid; Cytochrom | 2008 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiograph | 2010 |
The hydrolysis of striatal adenine- and guanine-based purines in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: 5'-Nucleotidase; Acid Anhydride Hydrolases; Adenine; Adrenergic Agents; Animals; Corpus Striatum; Di | 2011 |
Phenotype of the 202 adenine deletion in the parkin gene: 40 years of follow-up.
Topics: Adenine; Adult; Age of Onset; Aged; Disability Evaluation; Disease Progression; Family Health; Femal | 2011 |
Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors.
Topics: Adenine; Catalysis; Catalytic Domain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inh | 2011 |
Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy.
Topics: Adenine; alpha-Synuclein; Autophagy; Blotting, Western; Cell Line; Cell Survival; Curcumin; Genetic | 2013 |
A BIOCHEMICAL GLIA ERROR IN THE PARKINSON DISEASE.
Topics: Adenine; Cytosine; Globus Pallidus; Guanine; Neurochemistry; Neuroglia; Neurons; Nucleic Acids; Park | 1963 |
New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Anim | 2005 |
Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease.
Topics: Adenine; Adult; Age of Onset; Aged; Aged, 80 and over; Alleles; alpha-Synuclein; Glutathione Transfe | 2007 |
Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson's disease.
Topics: Adenine; Aged; Aged, 80 and over; Alleles; Cytochrome P-450 CYP2D6; Gene Deletion; Genetic Predispos | 2007 |
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Dihydroxyphenylalanine; Dopamine Agents; Functi | 2007 |
Absence of the mitochondrial A7237T mutation in Parkinson's disease.
Topics: Adenine; Base Sequence; DNA Primers; DNA, Mitochondrial; Electron Transport Complex IV; Frontal Lobe | 1995 |
Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells.
Topics: Adenine; Adenosine; Animals; Disease Models, Animal; Dopamine; Guanine; Guanosine; Hypoxanthine; Neo | 2000 |